15 Participants Needed

Telitacicept for IgA Nephropathy

Recruiting at 37 trial locations
RB
Overseen ByRemegen Biosciences
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: RemeGen Co., Ltd.
Must be taking: AEI/ARB, Diuretics
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should have stabilized medications for blood pressure, like AEI/ARB or diuretics, which suggests you may need to continue those.

What data supports the effectiveness of the drug Telitacicept for IgA Nephropathy?

Telitacicept is shown to be effective in treating IgA Nephropathy by targeting and inhibiting specific proteins (BLyS and APRIL) that are important in the disease's autoimmune processes, helping to improve kidney function and reduce symptoms like blood and protein in the urine.12345

Is Telitacicept safe for humans?

The available research does not provide specific safety data for Telitacicept (also known as RC-18, RCT-18, or Tai'ai) in humans, particularly for IgA Nephropathy or other conditions.12456

How is the drug telitacicept different from other treatments for IgA nephropathy?

Telitacicept is unique because it targets two specific proteins, BAFF and APRIL, which are involved in the immune system's role in IgA nephropathy. This dual-target approach helps reduce harmful immune activity in the kidneys, potentially improving outcomes for patients with this condition.12578

What is the purpose of this trial?

This trial tests an injectable medication called Telitacicept on patients with a kidney disease known as IgA nephropathy. The medication aims to help by adjusting the immune system to reduce kidney damage.

Eligibility Criteria

Inclusion Criteria

Your average 24-hour urine protein level is greater than 0.75 grams.
Your kidney function, as measured by estimated GFR, is above a certain level.
You are taking certain medications for high blood pressure.
See 1 more

Exclusion Criteria

You have important abnormal test results from your lab tests.
Your kidney function has decreased rapidly by more than 15 ml/min during the screening process.
People with weakened immune systems.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Double-blind Treatment

Participants receive either Telitacicept 160 mg, Telitacicept 240 mg, or placebo subcutaneous injection once weekly for 24 weeks

24 weeks
24 visits (in-person, weekly)

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 weeks
Regular visits as per secondary outcome measures

Open-label Extension (optional)

Participants may opt into continuation of treatment long-term

Treatment Details

Interventions

  • Telitacicept
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Telitacicept 240mgExperimental Treatment1 Intervention
Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
Group II: Telitacicept 160mgExperimental Treatment1 Intervention
Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
Group III: PlaceboPlacebo Group1 Intervention
Placebo subcutaneous injection once weekly, and a total of 24 doses

Telitacicept is already approved in China for the following indications:

🇨🇳
Approved in China as Tai'ai for:
  • Systemic lupus erythematosus (SLE)

Find a Clinic Near You

Who Is Running the Clinical Trial?

RemeGen Co., Ltd.

Lead Sponsor

Trials
84
Recruited
11,100+

Dr. Jianmin Fang

RemeGen Co., Ltd.

Chief Executive Officer since 2008

PhD in Molecular Biology

Dr. Ruyi He

RemeGen Co., Ltd.

Chief Medical Officer since 2023

MD

Findings from Research

Telitacicept is a promising dual-target biological agent that inhibits B cell activating factors (BAFF) and APRIL, which are crucial in the autoimmune pathways associated with IgA nephropathy (IgAN).
By improving renal immune complex function and reducing symptoms like hematuria and proteinuria, telitacicept shows potential for treating IgAN and other autoimmune diseases linked to B cell activity.
Role of telitacicept in the treatment of IgA nephropathy.Wu, L., Du, X., Lu, X.[2023]
Atacicept, a B-cell-targeted immunomodulator, demonstrated an acceptable safety profile in a phase II study involving 16 patients with IgA nephropathy, with most treatment-emergent adverse events being mild or moderate.
The treatment led to significant reductions in pathogenic Gd-IgA1 levels and early improvements in proteinuria, while renal function remained stable compared to a decline observed in the placebo group.
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.Barratt, J., Tumlin, J., Suzuki, Y., et al.[2022]
Immunosuppressive agents, particularly steroids, significantly lower the risk of progression to end-stage kidney disease (ESRD) in patients with IgA nephropathy, based on a systematic review of 13 trials involving 623 patients.
Alkylating agents were also effective in reducing proteinuria, a key indicator of kidney damage, suggesting that immunosuppressive treatments may be beneficial, although more high-quality studies are needed to determine optimal management strategies.
Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials.Samuels, JA., Strippoli, GF., Craig, JC., et al.[2022]

References

Role of telitacicept in the treatment of IgA nephropathy. [2023]
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria. [2022]
Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. [2022]
Corticosteroids in IgA nephropathy: a randomised controlled trial. [2022]
Progression of IgA nephropathy under current therapy regimen in a Chinese population. [2021]
Comparative effectiveness and safety for the treatments despite optimized renin-angiotensin system blockade among IgA nephropathy patients at high-risk of disease progression: A network meta-analysis of randomized controlled trials. [2023]
Telitacicept for autoimmune nephropathy. [2023]
Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security